Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Gene Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00949650
What this trial is testing

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungAdenocarcinoma
Boehringer Ingelheim 345
Not applicableWithdrawnNCT05737849
What this trial is testing

Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Looking for participantsNCT06775743
What this trial is testing

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Fudan University 53
Testing effectiveness (Phase 2)UnknownNCT05007938
What this trial is testing

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 30
Testing effectiveness (Phase 2)UnknownNCT02069418
What this trial is testing

Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient

Who this might be right for
Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer RecurrentNo EGFR Activating Mutation
University Hospital, Angers 80
Large-scale testing (Phase 3)UnknownNCT02125240
What this trial is testing

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma

Who this might be right for
EGFR Positive Non-small Cell Lung CancerAdenocarcinoma
Betta Pharmaceuticals Co., Ltd. 124
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Not applicableStudy completedNCT01788163
What this trial is testing

Asia Pacific and Russia Diagnostic Study for EGFR Testing

Who this might be right for
EGFR Mutation Status in aNSCLC Patients
AstraZeneca 3,500
Not applicableApproved For MarketingNCT01649284
What this trial is testing

Afatinib Expanded Access Program

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim
Not applicableNo Longer AvailableNCT02451852
What this trial is testing

AZD9291 US Expanded Access Program

Who this might be right for
EGFR T790M Mutation Positive NSCLC
AstraZeneca
Testing effectiveness (Phase 2)UnknownNCT05519293
What this trial is testing

Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation

Who this might be right for
Non-small Cell Lung Cancer
RedCloud Bio 76
Not applicableEnded earlyNCT03265496
What this trial is testing

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

Who this might be right for
Nsclc
Centre Oscar Lambret 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT06015503
What this trial is testing

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Avistone Biotechnology Co., Ltd. 139
Testing effectiveness (Phase 2)UnknownNCT06018688
What this trial is testing

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 44
Large-scale testing (Phase 3)Looking for participantsNCT06417814
What this trial is testing

Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-small Cell Lung Cancer
AstraZeneca 744
Post-approval studies (Phase 4)UnknownNCT04132102
What this trial is testing

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

Who this might be right for
Lung Squamous Cell Carcinoma
Shanghai Chest Hospital 20
Not applicableNo Longer AvailableNCT02547675
What this trial is testing

Rociletinib (CO-1686) USA Expanded Access Program

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc.
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Next Page